Paper41801545
Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.
Khatri VM and 12 others. J Neurooncol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression. Papers, record 41801545. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41801545
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References12
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36690161 | Concurrent Administration of Immune Checkpoint Inhibitors and Single Fraction Stereotactic Radiosurgery in Patients With Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma Brain Metastases. | Int J Radiat Oncol Biol Phys | 2023 | https://conductscience.org/library/papers/36690161 | PubMed |
| 2 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 3 | 39137386 | First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/39137386 | PubMed |
| 4 | 39883427 | Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti-PD-1 Therapy. | JAMA Oncol | 2025 | https://conductscience.org/library/papers/39883427 | PubMed |
| 5 | 28592387 | Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28592387 | PubMed |
| 6 | 37657227 | Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases. | Eur J Cancer | 2023 | https://conductscience.org/library/papers/37657227 | PubMed |
| 7 | 40295143 | Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/40295143 | PubMed |
| 8 | 38991283 | "Symptomatic" melanoma brain metastases: A call for clear definitions and adoption of standardized tools. | Eur J Cancer | 2024 | https://conductscience.org/library/papers/38991283 | PubMed |
| 9 | 26065612 | Response assessment criteria for brain metastases: proposal from the RANO group. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/26065612 | PubMed |
| 10 | 34774225 | Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/34774225 | PubMed |
| 11 | 36780608 | Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36780608 | PubMed |
| 12 | 29327059 | Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation. | JAMA Oncol | 2018 | https://conductscience.org/library/papers/29327059 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41801545
GET https://conductscience.org/api/papers/v1/41801545/authors